Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
As our understanding of the mechanisms of cancer increases, so does our understanding of cancer therapies and responses to them. As part of our celebration for the 25th anniversary of Nature Medicine, we bring you a special focus on the most up-to-date approaches transforming the landscape of cancer therapy. Also check out the most recent clinical trials published in Nature Medicine and in Nature, as well as a selection of research in the emerging field of clinical genomics.
Childhood cancers are developmentally distinct from adult cancers and arise from cellular reprogramming as a result of epigenetic mutations or gene fusions, providing unique therapeutic opportunities.
A neoadjuvant approach using combined anti-CTLA4/anti-PD1 treatment prior to lymph node surgery is evaluated in two phase I trials of later stage melanoma finding this a therapeutic angle worth pursuing.
The tumor immune microenvironment influences tumor progression and response to immunotherapy; its further characterization will improve therapeutic outcome.